Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial

• Published in: International journal of clinical practice (Esher) Vol. 63; no. 12; pp. 1702 - 1714
• Main Authors: Vardy, M. D., Mitcheson, H. D., Samuels, T.-A., Wegenke, J. D., Forero-Schwanhaeuser, S., Marshall, T. S., He, W.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.12.2009; Wiley-Blackwell; Hindawi Limited
• Subjects: Adult; Aged; Aged, 80 and over; Analysis of Variance; Biological and medical sciences; Clinical trials; Comparative studies; Double-Blind Method; Drug therapy; Effectiveness; Female; General aspects; Humans; Male; Medical sciences; Middle Aged; Muscarinic Antagonists - administration & dosage; Muscarinic Antagonists - adverse effects; Nephrology. Urinary tract diseases; Quality of Life; Quinuclidines - administration & dosage; Quinuclidines - adverse effects; Solifenacin Succinate; Tetrahydroisoquinolines - administration & dosage; Tetrahydroisoquinolines - adverse effects; Treatment Outcome; Urinary Bladder, Overactive - drug therapy; Urinary system involvement in other diseases. Miscellaneous; Urinary tract. Prostate gland; Urology; Young Adult; Human; Urinary system disease; Prognosis; Report; Patient; Urinary tract disease; Result; Medicine; Symptomatology; Anticholinergic agent; Cholinergic receptor; Solifenacin; Antimuscarinic agent; Double blind study; Evolution; Overactive bladder; Bladder disease; Muscarinic receptor; Antagonist
• ISSN: 1368-5031; 1742-1241
• DOI: 10.1111/j.1742-1241.2009.02209.x

Summary Aim:  The aim of this study was to evaluate the efficacy of solifenacin on symptom bother using the Overactive Bladder Questionnaire (OAB‐q). Methods:  In VIBRANT, a double‐blind, US‐based trial, patients with OAB for ≥ 3 months received flexibly dosed solifenacin or placebo for 12 weeks. At baseline and 4‐week intervals, patients completed the OAB‐q [symptom bother and health‐related quality of life (HRQL) scales] and 3‐day bladder diaries; other patient‐reported outcome measures were also assessed at baseline and week 12. The primary efficacy end‐point was the change from baseline to end of treatment (EOT) on the OAB‐q Symptom Bother scale. Adverse events (AEs) were monitored. Results:  At EOT, solifenacin (n = 377) vs. placebo (n = 374) significantly improved mean symptom bother (−29.9 vs. −20.4, p < 0.0001), HRQL total (25.3 vs. 16.7, p < 0.0001) and all HRQL domain scores (Ps < 0.0001). Solifenacin vs. placebo significantly improved daily episodes of urgency, incontinence and frequency but not nocturia. Significant separation from placebo was evident as early as week 4. Overall, significantly more solifenacin vs. placebo patients reported treatment benefit (84% vs. 63%), satisfaction (80% vs. 59%) and willingness to continue (79% vs. 60%; Ps< 0.0001). Treatment‐related AEs in solifenacin vs. placebo patients were dry mouth (13% vs. 2%), constipation (8% vs. 2%) and dry eye (2% vs. 0.3%). Conclusions:  As early as week 4 and through EOT, flexibly dosed solifenacin significantly improved OAB symptom bother and HRQL as well as the symptoms of urgency, frequency and incontinence compared with placebo. Significantly more solifenacin patients reported treatment benefit and satisfaction at week 12 compared with placebo.